Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
- 20 October 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (30), 4609-4615
- https://doi.org/10.1200/jco.2010.30.5474
Abstract
Purpose Src family kinases (SFKs) promote cancer progression and are commonly expressed in non–small-cell lung cancer (NSCLC), but the clinical effects of SFK inhibition in NSCLC are unknown. We conducted a phase II trial of the SFK inhibitor dasatinib for advanced NSCLC. We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a response to dasatinib. Patients and Methods Patients received dasatinib as first-line therapy. Response was measured by tumor size on computed tomography scans and by metabolic activity on positron emission tomography scans. Tissue samples taken before patients received dasatinib were tested for EGFR and Kras mutation and phosphorylated SFK expression. Results Thirty-four patients were enrolled. The overall disease control rate (partial responses plus stable disease) for dasatinib was 43%. One patient had a partial response to therapy. Eleven patients (32%) had a metabolic response to dasatinib. SFK activation and EGFR and Kras mutations in tumor tissue did not predict response to dasatinib. Significant toxicities included fatigue and dyspnea. The presence of a pleural effusion before dasatanib therapy predicted the development of a clinically significant effusion during therapy. Conclusion Dasatinib as a single agent had modest clinical activity that was lower than that generally observed in patients with NSCLC who receive chemotherapy. Pleural effusion was an expected and problematic toxicity that was successfully treated with steroids, diuretics, and dose interruptions. Marked activity in one patient and prolonged stable disease in four others suggested a potential subpopulation of patients with dasatinib-sensitive NSCLC.Keywords
This publication has 38 references indexed in Scilit:
- Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)Journal of Thoracic Oncology, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumorsCancer, 2010
- Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatinMolecular Cancer Therapeutics, 2009
- Src kinases as therapeutic targets for cancerNature Reviews Clinical Oncology, 2009
- Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted TherapyMolecular Cancer Research, 2009
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesionsJCI Insight, 2009